Skip to main content
Equibles
PLSH logo

PLSH · Panacea Life Sciences Holdings, Inc. · Metrics

Track PLSH — free

Use PLSH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PLSH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.08 At close · Nov 10
Rebalance outlook locked
Going-concern doubt — flagged May 6, 2024

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about the Company's ability to continue as a going concern for a period of 12 months from the issuance date of this report. Management cannot provide assurance that the Company will ultimately achieve profitable operations or become cash flow positive or raise additional debt and/or equity capital.”
View the 10-Q filed May 6, 2024
Market Cap
$1.46M
Shares
17.65M
Volume · Nov 10 1123 Avg daily vol (3M) 6856

PLSH metrics

55 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.08
Market cap
$1.46M

Price action

23 metrics
Price change (1W)
+0.0%
Price change (30D)
+25.5%
Price change (3M)
-17.2%
Price change (6M)
+176.0%
Price change (YTD)
+65.6%
Price change (1Y)
+38.0%
Trailing year
Price change (5Y)
—
52-week high
$0.14
52-week low
$0.03
Change from 52-week high
-40.9%
Change from 52-week low
+231.2%
Annualized volatility
261.7%
Annualized volatility (3M)
—
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
1.0
RSI (14D)
51.5
Price vs SMA 50
-3.8%
Price vs SMA 200
+44.7%
Avg volume (3M)
6,856
Relative volume
0.2
Average dollar volume
$562

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
17.65M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.5×
reciprocal yield 189.2%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-525.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
56.5%
Operating margin
-192.2%
Trailing 12 months
Net margin
-277.5%
Gross profit (TTM)
$1.56M
Operating profit (TTM)
−$5.31M
Net income (TTM)
−$7.67M
Trailing 12 months
Diluted EPS (TTM)
$-0.45
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.16
Gross profit per diluted share (TTM)
$0.09
Operating profit per diluted share (TTM)
$-0.31
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$-0.45
Operating cash flow per diluted share (TTM)
$-0.09
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$0.00
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.47

Growth

11 metrics
Revenue growth YoY
+55.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$2.76M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+10.2%
Year over year · more shares
Revenue CAGR (3Y)
-35.8%
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-44.0%
Debt / equity
—
Current ratio
0.2
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
0.0
Interest coverage
-3.3
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$107,643
Total assets
$17.41M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$1.57M
Capital expenditures (TTM)
$55,102
R&D (TTM)
$0
SG&A (TTM)
—
Stock compensation (TTM)
−$2.67M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1552189 CUSIP 69810P109 Visit website